American Diabetes Association (2021) Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diab Car 44(Suppl 1):111–124. https://doi.org/10.2337/dc21-s009

Article  CAS  Google Scholar 

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS et al (2015) American association of clinical endocrinologists and American college of endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract 21(Suppl 1):1–87. https://doi.org/10.4158/EP15672.GL

Article  PubMed  PubMed Central  Google Scholar 

Sanchez-Rangel E, Inzucchi SE (2017) Metformin: clinical use in type 2 diabetes. Diabetologia 60(9):1586–1593. https://doi.org/10.1007/s00125-017-4336-x

Article  CAS  PubMed  Google Scholar 

Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK, Wu T (2019) Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes Obes Metab. https://doi.org/10.1111/dom.13869

Article  PubMed  Google Scholar 

Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D’Addio F, Zuccotti GV, Fiorina P (2021) Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 171:105782. https://doi.org/10.1016/j.phrs.2021.105782

Article  CAS  PubMed  Google Scholar 

Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR (1999) Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diab Car 22(9):1501. https://doi.org/10.2337/diacare.22.9.1501

Article  CAS  Google Scholar 

Gao J, Xiong Q, Miao J, Zhang Y, Xia L, Lu M et al (2015) Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia. Biomed Rep 3(3):284–288. https://doi.org/10.3892/br.2015.434

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kjeld H, Mette B, Anne GS (2016) Insulin Aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs 76:41–74. https://doi.org/10.1007/s40265-015-0500-0

Article  CAS  Google Scholar 

Guideline on similar biological medicinal products, CHMP/437/04 Rev 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 23 Oct 2014

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 Rev1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf . Accessed 18 Dec 2014

Scientific considerations in demonstrating biosimilarity to a reference product (Guidance for Industry). https://www.fda.gov/media/82647/download. Accessed Apr 2015

Clinical pharmacology data to support a demonstration of biosimilarity to a reference product guidance for industry. https://www.fda.gov/media/88622/download. Accessed Dec 2016.

Mishra AG, Deshmane RB, Thappa DK et al (2023) In vitro biological characterization of recombinant insulin Aspart from biogenomics and originator insulin Aspart. BioDrugs. https://doi.org/10.1007/s40259-023-00607-4

Article  PubMed  Google Scholar 

Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10):1241–1252. https://doi.org/10.1038/nbt1252

Article  CAS  PubMed  Google Scholar 

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 Rev1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 18 Dec 2014

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C (2017) Introduction of biosimilar insulins in Europe. Diabet Med 34(10):1340–1353. https://doi.org/10.1111/dme.13400

Article  CAS  PubMed  PubMed Central  Google Scholar 

Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. https://www.fda.gov/media/125484/download. Accessed May 2019

Groot De, Anne S, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28(11):482–490. https://doi.org/10.1016/j.it.2007.07.011.PMID17964218

Article  PubMed  Google Scholar 

Baker M, Reynolds HM, Lumicisi B, Bryson CJ (2010) Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself 1(4):314–322. https://doi.org/10.4161/self.1.4.13904.PMC3062386.PMID21487506

Article  PubMed  PubMed Central  Google Scholar 

Lindsey BB, Armitage EP, Kampmann B, de Silva TI (2019) The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. Lancet Infect Dis 19(4):110–119. https://doi.org/10.1016/S1473-3099(18)30490-0

Article  Google Scholar 

WHO (2014) WHO Expert Committee on Biological Standardization. World Health Organization. ISBN 978–92–4–069262–6. OCLC 888748977

Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25(5):555–561. https://doi.org/10.1038/nbt1303

Article  CAS  PubMed  Google Scholar 

Schellekens H (2005) Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20(Suppl 6):3–9. https://doi.org/10.1093/ndt/gfh1092

Article  CAS  Google Scholar 

Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermüller J, Stadler PF et al (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83(2):219–227. https://doi.org/10.1016/j.ajhg.2008.07.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donnelly RP, Dickensheets H, O’Brien TR (2011) Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 32(9):443–450. https://doi.org/10.1016/j.it.2011.07.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28(6):625–652. https://doi.org/10.1210/er.2007-0002

Article  CAS  PubMed  Google Scholar 

Gupta SK (2011) Implications of ICH-E5: assessment of drug’s sensitivity to ethnic factors and necessity of a bridging study for global drug development. Perspect Clin Res 2(4):121–123. https://doi.org/10.4103/2229-3485.86874

Article  PubMed  PubMed Central  Google Scholar 

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A et al (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPSJ 16(4):658–673. https://doi.org/10.1208/s12248-014-9599-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devanarayan V, Smith WC, Brunelle RL, Seger ME, Krug K, Bowsher RR (2017) Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J 19(5):1487–1498. https://doi.org/10.1208/s12248-017-0107-3

Article  CAS  PubMed  Google Scholar 

Guideline on Immunogenicity assessment of therapeutic proteins, EMEA/CHMP/BMWP/14327/2006 Rev 1.https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 18 May 2017

Schellekens H (2008) Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 21(4):497–502

CAS  PubMed  Google Scholar